- Trial phase
- Approved
- Time to market
- Already approved and commercially available in the US (since March 2025), China (since Dec 2025), and India (since Oct 2026).
- Why 4/10
- Qfitlia is already FDA-approved and commercially launched in the US, with no pending PDUFA or pivotal readout in the next ~12 months; additional country approvals (e.g., EMA) are possible but not hard-dated. As a small part of Sanofi's massive diversified pipeline, even a major commercial surprise would not drive a large share-price move.
Qfitlia is already approved in the US (March 2025), China (Dec 2025), and India (Oct 2026). The next catalysts to watch are potential European Medicines Agency (EMA) approval and additional country-level launches, though no hard dates are publicly set. Commercial adoption and payer uptake in the US will determine whether the drug reaches its projected $500M-$1.5B peak sales range, but for Sanofi this is a modest contributor within a $50B+ revenue base.
Price Chart
Executive Summary
Qfitlia (fitusiran) is a first-in-class RNAi therapy approved by the FDA in March 2025 for routine prophylaxis of bleeding in hemophilia A and B patients aged 12 and older, with or without inhibitors. Developed by Sanofi (SNY) in partnership with Alnylam, it is the only antithrombin-lowering therapy for hemophilia and offers subcutaneous dosing as infrequently as once every two months. Phase 3 ATLAS trials showed a 71-90% reduction in annualized bleeding rates versus on-demand therapy. The drug carries a boxed warning for thrombosis and gallbladder disease. Additional approvals have been secured in China (Dec 2025) and India (Oct 2026). For Sanofi, a $105B market-cap diversified pharma giant, Qfitlia is a modest contributor with projected peak sales of $500M-$1.5B, facing entrenched competition from Roche's Hemlibra and other non-factor therapies.
How It Works
Qfitlia is a small interfering RNA (siRNA) drug that works by blocking the production of a protein called antithrombin, which normally acts as a natural brake on blood clotting. By lowering antithrombin levels, the drug shifts the patient's coagulation system toward a more clot-friendly state, compensating for the missing clotting factor that causes hemophilia. It is given as a shot under the skin once every two months.
Trial Status
Qfitlia was approved by the FDA on March 28, 2025, based on the Phase 3 ATLAS clinical program (ATLAS-INH, ATLAS-A/B, and ATLAS-OLE). The ATLAS-OLE open-label extension study (NCT03754790) is ongoing, evaluating the antithrombin-based dose regimen targeting AT levels of 15-35%. Published data showed fitusiran reduced annualized bleeding rates by approximately 71-73% versus on-demand therapy in patients without and with inhibitors, respectively, and by up to 90% versus on-demand bypassing agents.
The Two-Sided Case
Upcoming Catalysts
- Potential European Medicines Agency (EMA) approval decision, though no date has been publicly set.
- Additional country-level approvals and launches (e.g., Japan, other Asia-Pacific markets).
- Ongoing ATLAS-OLE long-term safety and efficacy data readouts at medical conferences.
- Quarterly commercial sales updates in Sanofi earnings reports, providing early adoption signals.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Sanofi 6-K SNY ·Originating report